Genentech Omaspect GX30191 EXT

Currently Enrolling

A multi-center, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with GA secondary to AMD who have completed a Roche-Sponsored Study

Duration: 96 weeks

This entry was posted in Uncategorized. Bookmark the permalink.